JP2003012668A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003012668A5 JP2003012668A5 JP2002126869A JP2002126869A JP2003012668A5 JP 2003012668 A5 JP2003012668 A5 JP 2003012668A5 JP 2002126869 A JP2002126869 A JP 2002126869A JP 2002126869 A JP2002126869 A JP 2002126869A JP 2003012668 A5 JP2003012668 A5 JP 2003012668A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound according
- alkyl
- hydrogen atom
- alkyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002126869A JP3602513B2 (ja) | 2001-04-27 | 2002-04-26 | アゾリル基を有するキノリン誘導体およびキナゾリン誘導体 |
| NL300927C NL300927I9 (nl) | 2001-04-27 | 2018-01-31 | Tivozanib of een zout, solvaat of hydraat ervan, in het bijzonder het hydrochloride-monohydraat |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001-132775 | 2001-04-27 | ||
| JP2001132775 | 2001-04-27 | ||
| JP2002126869A JP3602513B2 (ja) | 2001-04-27 | 2002-04-26 | アゾリル基を有するキノリン誘導体およびキナゾリン誘導体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004101164A Division JP2004224800A (ja) | 2001-04-27 | 2004-03-30 | アゾリル基を有するキノリン誘導体およびキナゾリン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003012668A JP2003012668A (ja) | 2003-01-15 |
| JP3602513B2 JP3602513B2 (ja) | 2004-12-15 |
| JP2003012668A5 true JP2003012668A5 (enExample) | 2004-12-16 |
Family
ID=26614489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002126869A Expired - Lifetime JP3602513B2 (ja) | 2001-04-27 | 2002-04-26 | アゾリル基を有するキノリン誘導体およびキナゾリン誘導体 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3602513B2 (enExample) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8815241B2 (en) | 2005-11-07 | 2014-08-26 | Eisai R&D Management Co., Ltd. | Use of combination of anti-angiogenic substance and c-kit kinase inhibitor |
| US8952035B2 (en) | 2007-11-09 | 2015-02-10 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| US8962650B2 (en) | 2011-04-18 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
| US8969344B2 (en) | 2005-08-02 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
| US9006256B2 (en) | 2006-05-18 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Antitumor agent for thyroid cancer |
| US9012458B2 (en) | 2010-06-25 | 2015-04-21 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| US9504746B2 (en) | 2004-09-17 | 2016-11-29 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003033472A1 (en) * | 2001-10-17 | 2003-04-24 | Kirin Beer Kabushiki Kaisha | Quinoline or quinazoline derivatives inhibiting auto- phosphorylation of fibroblast growth factor receptors |
| US7994159B2 (en) | 2003-03-10 | 2011-08-09 | Eisai R&D Management Co., Ltd. | c-Kit kinase inhibitor |
| CN101511793B (zh) * | 2006-08-28 | 2011-08-03 | 卫材R&D管理有限公司 | 针对未分化型胃癌的抗肿瘤剂 |
| KR101445892B1 (ko) | 2007-01-29 | 2014-09-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 미분화형 위암 치료용 조성물 |
| EP3444363B1 (en) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| AU2013364953A1 (en) | 2012-12-21 | 2015-04-30 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
| WO2014185540A1 (en) | 2013-05-14 | 2014-11-20 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| KR102329681B1 (ko) | 2014-08-28 | 2021-11-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
| KR20250024102A (ko) | 2015-02-25 | 2025-02-18 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 고미 억제 방법 |
| AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
| ES2886107T3 (es) | 2015-06-16 | 2021-12-16 | Prism Biolab Co Ltd | Antineoplásico |
| SG11201801083UA (en) | 2015-08-20 | 2018-03-28 | Eisai R&D Man Co Ltd | Tumor therapeutic agent |
| CA3036474A1 (en) | 2016-09-13 | 2018-03-22 | Kyowa Hakko Kirin Co., Ltd. | Therapeutic agent for an ophthalmic disease comprising a vegf receptor inhibitor |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| US20200197384A1 (en) | 2017-05-16 | 2020-06-25 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
-
2002
- 2002-04-26 JP JP2002126869A patent/JP3602513B2/ja not_active Expired - Lifetime
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9504746B2 (en) | 2004-09-17 | 2016-11-29 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide |
| US8969344B2 (en) | 2005-08-02 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
| US9006240B2 (en) | 2005-08-02 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
| US8815241B2 (en) | 2005-11-07 | 2014-08-26 | Eisai R&D Management Co., Ltd. | Use of combination of anti-angiogenic substance and c-kit kinase inhibitor |
| US9006256B2 (en) | 2006-05-18 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Antitumor agent for thyroid cancer |
| US8952035B2 (en) | 2007-11-09 | 2015-02-10 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| US9012458B2 (en) | 2010-06-25 | 2015-04-21 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| US8962650B2 (en) | 2011-04-18 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003012668A5 (enExample) | ||
| JP2005500311A5 (enExample) | ||
| RU2317294C2 (ru) | (имидазол-1-илметил)пиридазин в качестве блокатора nmda рецептора | |
| JP2006508065A5 (enExample) | ||
| JP2004501930A5 (enExample) | ||
| CA2445333A1 (en) | Quinoline derivatives and quinazoline derivatives having azolyl group | |
| JP2006517572A5 (enExample) | ||
| JP2004532209A5 (enExample) | ||
| JP2011500658A5 (enExample) | ||
| JP2007512299A5 (enExample) | ||
| JP2006524222A5 (enExample) | ||
| WO2005037781A3 (fr) | Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique | |
| JP2006509749A5 (enExample) | ||
| RU2001132139A (ru) | Имидазохинолины с сульфонамидными или сульфамидным замещением | |
| JP2007508359A5 (enExample) | ||
| RU2001112421A (ru) | Бензоилциклогександионы, способ их получения и их применение в качестве гербицидов и регуляторов роста растений | |
| JP2009507896A5 (enExample) | ||
| BRPI0608732A2 (pt) | composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto | |
| JP2005511547A5 (enExample) | ||
| JP2005530811A5 (enExample) | ||
| JP2005518357A5 (enExample) | ||
| JP2002520316A5 (enExample) | ||
| JP2009518365A5 (enExample) | ||
| RU2009102270A (ru) | Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы | |
| CA2547347A1 (en) | Diazaindole-dicarbonyl-piperazinyl antiviral agents |